501 related articles for article (PubMed ID: 22419670)
21. Benign course of tumour-like multiple sclerosis. Report of five cases and literature review.
Turatti M; Gajofatto A; Bianchi MR; Ferrari S; Monaco S; Benedetti MD
J Neurol Sci; 2013 Jan; 324(1-2):156-62. PubMed ID: 23151425
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
[TBL] [Abstract][Full Text] [Related]
23. Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes.
Villar LM; Espiño M; Roldán E; Marín N; Costa-Frossard L; Muriel A; Alvarez-Cermeño JC
Mult Scler; 2011 Jun; 17(6):690-4. PubMed ID: 21436320
[TBL] [Abstract][Full Text] [Related]
24. Pediatric tumefactive demyelination: case series and review of the literature.
McAdam LC; Blaser SI; Banwell BL
Pediatr Neurol; 2002 Jan; 26(1):18-25. PubMed ID: 11814730
[TBL] [Abstract][Full Text] [Related]
25. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.
Kepes JJ
Ann Neurol; 1993 Jan; 33(1):18-27. PubMed ID: 8494332
[TBL] [Abstract][Full Text] [Related]
26. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion.
Law M; Meltzer DE; Cha S
Neuroradiology; 2002 Dec; 44(12):986-9. PubMed ID: 12483443
[TBL] [Abstract][Full Text] [Related]
27. [Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].
Launay M; Lebrun C; Giordana E; Chanalet S; Thomas P
Rev Neurol (Paris); 2011 Jan; 167(1):14-22. PubMed ID: 20739040
[TBL] [Abstract][Full Text] [Related]
28. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.
Lucchinetti CF; Gavrilova RH; Metz I; Parisi JE; Scheithauer BW; Weigand S; Thomsen K; Mandrekar J; Altintas A; Erickson BJ; König F; Giannini C; Lassmann H; Linbo L; Pittock SJ; Brück W
Brain; 2008 Jul; 131(Pt 7):1759-75. PubMed ID: 18535080
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome.
Ferraro D; Simone AM; Bedin R; Galli V; Vitetta F; Federzoni L; D'Amico R; Merelli E; Nichelli PF; Sola P
J Neuroimmunol; 2013 Apr; 257(1-2):76-81. PubMed ID: 23434160
[TBL] [Abstract][Full Text] [Related]
30. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis.
Zipoli V; Hakiki B; Portaccio E; Lolli F; Siracusa G; Giannini M; Pantoni L; Pescini F; Sorbi S; Amato MP
Mult Scler; 2009 Apr; 15(4):472-8. PubMed ID: 19153171
[TBL] [Abstract][Full Text] [Related]
31. Biopsy-Supported Tumefactive Demyelination of the Central Nervous System in Children.
Hanumanthe SB; Francisco C; Hart J; Graves J; Waubant E
J Child Neurol; 2016 Dec; 31(14):1528-1533. PubMed ID: 27572815
[TBL] [Abstract][Full Text] [Related]
32. Acute fulminant demyelinating disease: a descriptive study of 60 patients.
de Seze J; Debouverie M; Zephir H; Lebrun C; Blanc F; Bourg V; Wiertlewski S; Pittion S; Laplaud D; Le Page E; Deschamps R; Cabre P; Pelletier J; Malikova I; Clavelou P; Jaillon V; Defer G; Labauge P; Gout O; Boulay C; Edan G; Vermersch P
Arch Neurol; 2007 Oct; 64(10):1426-32. PubMed ID: 17923626
[TBL] [Abstract][Full Text] [Related]
33. [Late onset multiple sclerosis].
Delalande S; De Seze J; Ferriby D; Stojkovic T; Vermersch P
Rev Neurol (Paris); 2002 Nov; 158(11):1082-7. PubMed ID: 12451340
[TBL] [Abstract][Full Text] [Related]
34. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
Jain RS; Khan I; Kandelwal K; Desai T
Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
[TBL] [Abstract][Full Text] [Related]
35. Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion.
Abdoli M; Freedman MS
Mult Scler Relat Disord; 2015 Nov; 4(6):555-66. PubMed ID: 26590662
[TBL] [Abstract][Full Text] [Related]
36. Clinical isolated syndrome: a 3-year follow-up study in China.
Liu Y; Duan Y; Yu C; Qin W; Chen H; Dong H; Ye J; Butzkueven H; Li K
Clin Neurol Neurosurg; 2011 Oct; 113(8):658-60. PubMed ID: 21680087
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of vanishing tumors in the brain: how should a lesion mimicking primary CNS lymphoma be managed?
Okita Y; Narita Y; Miyakita Y; Ohno M; Fukushima S; Maeshima A; Kayama T; Shibui S
Clin Neurol Neurosurg; 2012 Nov; 114(9):1217-21. PubMed ID: 22445618
[TBL] [Abstract][Full Text] [Related]
38. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
39. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Masjuan J; Alvarez-Cermeño JC; García-Barragán N; Díaz-Sánchez M; Espiño M; Sádaba MC; González-Porqué P; Martínez San Millán J; Villar LM
Neurology; 2006 Feb; 66(4):576-8. PubMed ID: 16505315
[TBL] [Abstract][Full Text] [Related]
40. ADC measurements in various patterns of multiple sclerosis lesions.
Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
